Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Oramed Pharmaceuticals, Inc. (ORMP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.13+3.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ORMP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
successful completion of Phase III trials for ORMD-0801 | Successful Phase II trials could lead to significant revenue. | Intact | failure to complete Phase III trials by FY27 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, fragile business setup rather than a proven durable compounder. The long-term thesis is on watch: recent financial performance is weak versus its industry group, and the evidence does not show a fresh break in the thesis.
The snapshot labels ORMP cheap versus peers, while also flagging valuation and execution concerns. The market’s exact expectations are not provided, so the expectations gap is unclear; the evidence points to weak execution as a key concern.
Near term, erratic earnings surprises and the most recent quarterly miss point to elevated risk of another earnings miss. Management is rated neutral, and the snapshot provides little detail on how the acquisition completed in March may affect results over the multi-year view.
The near-term setup depends partly on whether earnings stabilize and execution improves. A weakening jobs trend could weigh on cyclical names, while stronger results and guidance from healthcare bellwethers could support the sector backdrop; misses or lower guidance could weaken that support.
Over the next 1 to 3 years, the thesis remains fragile and dependent on better execution, with elevated near-term earnings risk balanced by a stronger healthcare sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Oramed Pharmaceuticals, Inc.'s published investment case. The stated target is >=60% gross margin. |
| Broken |
| gross margin falls below 50% |
Gross margin: 0.65% FY2025-Q1; GAAP. Published target: >=60% gross margin. Target period is not explicitly aligned with this observation. May 15, 20250.65 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
revenue growth returning to positive territory | A supporting condition in Oramed Pharmaceuticals, Inc.'s published investment case. The stated target is >=10% YoY growth by FY28. | Intact | revenue growth remains negative beyond FY27 | Required source inputs unavailable Cannot calculate Revenue growth from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.82 → $-0.82 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-27 | $-0.82 | $778,593 | 1 / 1 |
| 2026-08-28 | $-0.82 | $778,593 | 1 / 1 |
| 2026-08-29 | $-0.82 | $778,593 | 1 / 1 |
| 2026-08-30 | $-0.82 | $778,593 | 1 / 1 |
| 2026-08-31 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-01 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-02 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-03 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-04 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-05 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-06 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-07 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-08 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-09 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-10 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-11 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-12 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-13 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-14 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-15 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-16 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-17 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-18 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-19 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-20 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-21 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-22 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-23 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-24 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-25 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-26 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-27 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-28 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-29 | $-0.82 | $778,593 | 1 / 1 |
| 2026-09-30 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-01 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-02 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-03 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-04 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-05 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-06 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-07 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-08 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-09 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-10 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-11 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-12 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-13 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-14 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-15 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-16 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-17 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-18 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-19 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-20 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-21 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-22 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-23 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-24 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-25 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-26 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-27 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-28 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-29 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-30 | $-0.82 | $778,593 | 1 / 1 |
| 2026-10-31 | $-0.82 | $778,593 | 1 / 1 |
| 2026-11-01 | $-0.82 | $778,593 | 1 / 1 |
| 2026-11-02 | $-0.82 | $778,593 | 1 / 1 |
| 2026-11-03 | $-0.82 | $778,593 | 1 / 1 |
| 2026-11-04 | $-0.82 | $778,593 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.